Barclays
HGEN

Barclays’s HUMANIGEN, INC. HGEN Stock Holding History

Barclays’s Portfolio HGEN Stock Details HGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-88
Closed – – 5255
2022
Q2 		$0 Buy
+88
New +$198 ﹤0.01% 5389

Other funds holding HGEN

GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Barclays's HGEN Position: Q3 2022 in Review

Barclays sold out of HUMANIGEN, INC. (HGEN) in Q3 2022, closing a stake of 88 shares.

Barclays first reported a position in HGEN in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 53 funds tracked by Wall St. Rank hold HGEN as of Q3 2022.

  • Barclays reported no remaining HUMANIGEN, INC. position as of Q3 2022 after selling out during the quarter.
  • Barclays sold 88 HUMANIGEN, INC. shares in Q3 2022.
  • Barclays first reported a position in HUMANIGEN, INC. in Q2 2022 and held it in 1 quarter.
  • Barclays's HUMANIGEN, INC. position peaked at $0 in Q2 2022.
  • 53 funds tracked by Wall St. Rank held HUMANIGEN, INC. as of Q3 2022.

Based on Barclays's 13F filing for Q3 2022, filed 3 Nov 2022.